Full-Time

Principal Scientist

Cancer Biology

General Proximity

General Proximity

11-50 employees

Seed-stage platform for induced proximity drugs

No salary listed

San Francisco, CA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Cell Biology
Requirements
  • PhD in Cancer Biology, Cell Biology, or related field
  • 5-7+ years of industry experience
  • Deep understanding of small-molecule drug discovery and its relationship to human disease
  • Exceptional leadership, interpersonal, and communication skills, with a track record of managing high-performing, multidisciplinary teams
  • Strong experience with cellular and molecular biology, including cancer cell line work and associated assays, stable cell line generation (lentiviral and CRISPR-based systems), co-immunoprecipitation/pull-down assays, RNA sequencing, global proteomics, flow cytometry, plasmid design/cloning, etc.
  • Experience with pre-clinical characterization and mechanistic elucidation of small-molecule drug candidates
  • Mechanistic studies of cancer cell signaling and post-translational modification analysis
  • Phenotypic assay development for cancer drug discovery (low to high throughput)
  • Small molecule drug development campaigns (hit discovery, hit validation, dose-response studies, structure-activity relationship and mechanism of action studies)
  • Proficiency in managing a team of exceptional scientists and research associates
  • Target/indication selection
  • Animal models of cancer (genetically engineered mouse models, orthotopic, xenograft models), in vivo study design, and pharmacokinetics/pharmacodynamics interpretation
  • Managing contract research organizations for in vitro and in vivo studies
  • Grant writing
Responsibilities
  • Lead and manage the Biology Team and collaborate closely with the Platform Team in developing core drug discovery technology
  • Develop phenotypic assays
  • Establish pre-clinical in vitro and in vivo studies
  • Perform mechanistic studies on lead drug molecules
  • Spearhead forays into new oncology indications
  • Grant writing
Desired Qualifications
  • Experience navigating Investigational New Drug enabling studies and working on teams that have successfully advanced research to the clinic
  • Experience working at the interface of cancer biology and chemistry
  • Familiarity or experience with PROTAC/next-generation induced proximity medicines technologies
  • Experience with protein-protein interaction techniques (for example, bioluminescence resonance energy transfer, APEX/BioID, AlphaScreen)

Preparing a concise company summary based on provided description.

Company Size

11-50

Company Stage

Seed

Total Funding

$16.1M

Headquarters

San Francisco, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Daiichi Sankyo collaboration advances OmniTAC oncology candidates via Boston institute.
  • Daewoong Pharmaceutical investment funds induced proximity drugs for cardiovascular and neurodegenerative diseases.
  • $16M seed from Felicis, Y Combinator accelerates $250B market undruggable targets.

What critics are saying

  • Cash from $16M seed exhausts by mid-2026 without Series A proof-of-concept.
  • Daiichi Sankyo exclusivity blocks Arvinas-competing deals for 12-18 months.
  • Novartis poaches Scripps scientists like Andreas Maderna within 6-12 months.

What makes General Proximity unique

  • OmniTAC platform uses unbiased Effectome scanning for mechanism-agnostic proximity therapeutics.
  • Targets undruggable proteins in oncology, cardiometabolic, neurodegeneration, and longevity diseases.
  • Team delivered 40+ FDA-approved medicines, 175+ INDs, and 240 patents.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at General Proximity who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

11%
Business News Today
Nov 12th, 2025
General Proximity inks Daiichi Sankyo deal to push precision small molecules into oncology

General Proximity inks Daiichi Sankyo deal to push precision small molecules into oncology. General Proximity partners with Daiichi Sankyo to develop proximity-based cancer drugs using OmniTAC. Discover how this biotech is redefining drug discovery. General Proximity, a San Francisco-based biotechnology company developing proximity-induced medicines, has signed a strategic multi-target collaboration with Daiichi Sankyo Co., Ltd. to co-develop cancer treatments using its proprietary OmniTAC discovery platform. The partnership, routed through the Daiichi Sankyo Research Institute in Boston, will focus on identifying first-in-class therapeutic candidates capable of modulating proteins traditionally viewed as "undruggable" in oncology.

VC News Daily
Jan 3rd, 2025
General Proximity Raises $16M Funding

General Proximity, a biotech platform company, has emerged from stealth with $16M in funding. The oversubscribed seed round was led by Aydin Senkut of Felicis, with participation from Y Combinator, age1, Modi Ventures, Wilson Sonsini, and angel investors like Jeff Dean and Ben Mann. The funds will accelerate the development of treatments targeting undruggable proteins related to cancer, cardiometabolic disease, neurodegeneration, and longevity.

PR Newswire
Jan 3rd, 2025
General Proximity Raises $16M for Undruggable Targets

General Proximity has emerged from stealth with $16M to develop treatments for undruggable proteins linked to cancer, cardiometabolic disease, neurodegeneration, and longevity using its OmniTAC platform. The $8M seed round was led by Aydin Senkut at Felicis. Other investors include Y Combinator and Jim Dahl. The company aims to revolutionize drug discovery with a potential market exceeding $250 billion annually.

CALÓ News
Jan 3rd, 2025
General Proximity De-Stealths with $16M to Pioneer Next-Gen Induced Proximity Medicines for 'Undruggable' Targets

SAN FRANCISCO, Jan. 3, 2025 /PRNewswire/ - General Proximity, a breakthrough biotech platform company, today announced its emergence from stealth, unveiling its proprietary OmniTAC platform designed to pioneer the next generation of induced proximity medicines.

VentureCapital.com
Jan 3rd, 2025
General Proximity Unveils OmniTAC Platform with $16M Seed Funding

Biotech platform General Proximity has emerged from stealth mode, securing $16 million in seed funding to drive the development of induced proximity medicines targeting undruggable proteins.